| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
Cell lines | Twelve human myeloma cell lines |
Preparation method | The solubility of this compound in DMSO is >19.85 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 24 h |
Applications | In twelve HMCLs, treatment with KPT-276 (≤ 1 μM) for 72 h reduced cell viability with a median IC50 value of approximately 160 nM. KPT-276 treatment reduced c-Myc, CDC25A and BRD4 levels in both MM1.S and OCI-MY5. Treatment with KPT-276 for 24 h induced cell cycle arrest in MM1.S cells. |
Animal models | Athymic NCr-nu/nu mice bearing MM1.S cells, Vk*MYC mouse model |
Dosage form | Oral gavage, 150 mg/kg, 3 days/week for 3 weeks; |
Application | In a xenograft MM1.S MM model, the tumor volume significantly decreased after treatment with KPT-276 (12 days). KPT-276 reduced monoclonal spikes in the Vk*MYC transgenic MM mouse model, and inhibited tumor growth in a xenograft MM mouse model. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| 产品描述 | KPT-276, analog of KPT-185, is a selective inhibitor of nuclear export (SINE) and CRM1 [1]. Chromosomemaintenance protein 1 (CRM1) is a nuclear export receptor involved in the active transport of transcription factors, cell-cycle regulators, tumor suppressors and RNA molecules. In cancer, CRM1 is overexpression and overactive transport [1]. KPT-276 is an orally bioavailable and selective CRM1 inhibitor that irreversibly binds to CRM1 and blocks CRM1-mediated nuclear export [1]. In human multiple myeloma (MM) cell lines (HMCLs), KPT-276 irreversibly and specifically inhibited the nuclear export of XPO1, which encoded CRM1 and significantly reduced the viability of HMCLs. In bone marrow cells isolated from MM patients, KPT-276 induced apoptosis. Also, KPT-276 downregulated the expression of c-MYC, CDC25A and BRD4, which caused G1/S phase arrest [2]. In a xenograft human acute myeloid leukemia (AML) murine model, KPT-276 significantly increased the survival of mice and reduced the amount of white blood cells. Also, KPT-276 significantly reduced spleen weight and FLT3 protein expression [1]. In a xenograft MM mouse model, KPT-276 inhibited tumor growth [2]. References: |
m.cnreagent.com